TUSC2 therapies
A method for predicting a subject's response to a TUSC2 therapy is provided. In particular, a subject's response is predicted based on the proportion of cancers cells that are apoptotic. Also provided is a method of treating a subject previously predicted to have a favorable response with a TUSC2 therapy. Methods for treating cancer by administration of a TUSC2 therapeutic in conjunction with an EGFR inhibitor and/or a protein kinase inhibitor are also disclosed. Kits and reagents for use in TUSC2 therapy are provided.
1. A method for treating a human subject having a cancer, wherein it was determined that at least 10% of the pretreated cells of said cancer, having been obtained by biopsy from said subject, are apoptotic, the method comprising administering a TUSC2 therapy to the subject.
2. The method of claim 1 , wherein the TUSC2 therapy comprises administration of a TUSC2 expression vector.
3. The method of claim 2 , wherein the TUSC2 expression vector is plasmid DNA.
4. The method of claim 3 , wherein the plasmid is pLJ143/KGB2/FUS1.
5. The method of claim 2 , wherein the TUSC2 expression vector is provided in a liposome.
6. The method of claim 5 , wherein the liposome is a DOTAP:cholesterol liposome.
7. The method of claim 6 , wherein the DOTAP:cholesterol ratio is between about 1.5:1 and 1:1.5.
8. The method of claim 6 , wherein the TUSC2 expression vector and DOTAP:cholesterol liposome are administered in a dose of from about 0.01 mg/kg to about 0.10 mg/kg.
9. The method of claim 1 , wherein it was previously determined that at least 20% of the cells of said cancer are apoptotic.
10. The method of claim 1 , further comprising administering at least a second anti-cancer therapy to the subject.
11. The method of claim 10 , wherein the second anti-cancer therapy is chemotherapy, radiotherapy, gene therapy, surgery, hormonal therapy, anti-angiogenic therapy or cytokine therapy.
12. The method of claim 11 , wherein the second anti-cancer therapy is an EGFR inhibitor.
13. The method of claim 1 , wherein the cancer is a lung cancer.
14. The method of claim 13 , wherein the lung cancer is a non-small cell lung cancer.
15. The method of claim 13 , wherein the cancer is a metastatic lung cancer.
16. The method of claim 1 , wherein the cancer is resistant to at least a first chemotherapy.
17. The method of claim 16 , wherein the cancer is resistant to a platinum-based chemotherapy.
18. The method of claim 1 , wherein the TUSC2 therapy comprises administration of a TUSC2 polypeptide.
19. The method of claim 18 , wherein the TUSC2 polypeptide is myristoylated.
20. The method of claim 18 , wherein the TUSC2 polypeptide is comprised in a nanoparticle.
21. The method of claim 20 , wherein the nanoparticle is a lipid-based nanoparticle, a superparamagnetic nanoparticle, a nanoshell, a semiconductor nanocrystal, a quantum dot, a polymer-based nanoparticle, a silicon-based nanoparticle, a silica-based nanoparticle, a metal-based nanoparticle, a fullerene or a nanotube.